The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1998-3832
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus ; day:13 ; month:8 ; year:2020 ; pages:1-9
International journal of diabetes in developing countries ; (13.8.2020), 1-9
- Urheber
-
Zhang, Xueyang
Bai, Ran
Jia, Yong
Zong, Junwei
Wang, Yongbo
Dong, Yanan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s13410-020-00857-w
- URN
-
urn:nbn:de:101:1-2020100703304766809285
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhang, Xueyang
- Bai, Ran
- Jia, Yong
- Zong, Junwei
- Wang, Yongbo
- Dong, Yanan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Non-alcoholic fatty liver disease
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Artificial intelligence in nonalcoholic fatty liver disease
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Non-alcoholic fatty liver disease
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Artificial intelligence in nonalcoholic fatty liver disease
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Non-alcoholic fatty liver disease
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Artificial intelligence in nonalcoholic fatty liver disease
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease